Jinhui Xue

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

An empirical power comparison of directional goodness-of-fit tests for 2-PL IRT model under different intercept patterns.

An empirical power comparison of directional goodness-of-fit tests for 2-PL IRT model under different intercept patterns.

Journal: Journal of applied statistics

Published: September 03, 2026

Correction to: Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy.

Correction to: Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy.

Journal: BMC cancer

Published: August 13, 2026

SMARCA4-deficient lung adenocarcinoma with oral cavity metastasis: a case report.

SMARCA4-deficient lung adenocarcinoma with oral cavity metastasis: a case report.

Journal: BMC oral health

Published: March 12, 2026

The Oncogenic EGFR-SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer.

The Oncogenic EGFR-SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer.

Journal: Cancer discovery

Published: November 01, 2025

FAK activation drives non-genetic adaptive survival of ALK-rearranged lung cancer under tyrosine kinase inhibitor treatment.

FAK activation drives non-genetic adaptive survival of ALK-rearranged lung cancer under tyrosine kinase inhibitor treatment.

Journal: Journal of genetics and genomics = Yi chuan xue bao

Published: October 26, 2025

Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors.

Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors.

Journal: The oncologist

Published: August 07, 2025

JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial.

JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial.

Journal: Cancer cell

Published: August 01, 2025

Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK + and ROS1 + non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial.

Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK + and ROS1 + non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial.

Journal: EClinicalMedicine

Published: May 08, 2025

Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study.

Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 20, 2025

HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancer.

HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancer.

Journal: Journal of translational medicine

Published: January 09, 2025

Efficacy of antiangiogenic therapy in patients with advanced SMARCA4-deficient thoracic tumor.

Efficacy of antiangiogenic therapy in patients with advanced SMARCA4-deficient thoracic tumor.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 06, 2025

Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study.

Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study.

Journal: Cell reports. Medicine

Published: December 18, 2024

Showing 1-12 of 26

Last Updated: 09/26/2026